Cerus (CERS) AI Stock Analysis

• Market Cap: $275.27M
• Dividend Yield: N/A
• Average Volume (3M): 1.31M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.45
• Revenue Growth: 13.06%
• EPS Growth: 41.50%
• Country: US
• Employees: 614
• Sector: Healthcare
• Sector Strength: 55
• Industry: Medical - Devices
• EPS (TTM): -0.04
• Shares Outstanding: 191,160,480
• 10 Day Avg. Volume: 1,968,236
• 30 Day Avg. Volume: 1,311,577
• PEG Ratio: 0.60
• Price to Book (P/B): 9.53
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -23.33
• Enterprise Value/Market Cap: 2.53
• Enterprise Value/Revenue: 0.98
• Enterprise Value/Gross Profit: 6.71
• Enterprise Value/Ebitda: -18.13
• 1Y Price Target: $4.67
• Price Target Upside: 228.87% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

• Rating: 64 Neutral
• Price Target: $1.50 ▲(5.63%Upside)

Cerus Corporation is poised for growth with strong revenue performance and positive earnings call highlights, particularly in North America. While the technical analysis shows some bullish momentum, valuation challenges persist due to negative earnings. The company's ability to manage tariffs and improve profitability will be crucial to future prospects.

Positive Factors

Product Approval

CERS landed CE Mark for its next-generation Illuminator well ahead of expectations, which could mark a source of upside to guidance.

Profitability

CERS delivered positive adjusted EBITDA of $5.7M for the full year, indicating a productive quarter from a profitability standpoint.

Revenue Growth

Strength in North America and IFC propelled CERS to 13% revenue growth.

Negative Factors

Product Approval Setback

Recall last year, CERS' CE Mark review for INTERCEPT RBCs concluded without an approval, marking a disappointing setback for the company.

Regional Performance

Growth was partially offset by a decline of 4% in the company's EMEA segment, though this was largely due to the impact of foreign exchange.

Cerus Business Overview & Revenue Model

Company Description

Cerus Corporation (CERS) is a biomedical products company focused on safeguarding the world's blood supply. The company is a leader in blood safety innovation, primarily known for its INTERCEPT Blood System, which is designed to reduce the risk of transfusion-transmitted infections by inactivating a wide range of pathogens in donated blood components. Cerus operates in the healthcare and biotechnology sectors, providing solutions that help blood centers and hospitals improve the safety and availability of blood products.

How the Company Makes Money

Cerus Corporation generates revenue primarily through the sale of its INTERCEPT Blood System, which includes kits, devices, and consumables used for pathogen inactivation in blood components like platelets and plasma. The company earns money by supplying these systems to blood centers and hospitals worldwide, who are the primary customers. Additionally, Cerus engages in strategic partnerships and collaborations with various healthcare organizations and government entities, which can lead to funding, grants, or joint ventures that support product development and market expansion. Revenue is also influenced by regulatory approvals and the adoption of blood safety protocols that mandate or recommend the use of systems like INTERCEPT.

Cerus Financial Statement Overview

Summary

Cerus shows steady revenue growth with a healthy gross profit margin of 56.00%. However, ongoing net losses and negative profit margins indicate significant operational challenges. The balance sheet is moderately leveraged, and while cash flow trends are positive, achieving profitability remains a primary concern.

Income Statement

Cerus has shown a steady increase in revenue over the years, with a TTM revenue growth rate of 2.71% from the previous annual report. Gross profit margin is healthy at 56.00% for TTM, indicating efficient cost management on direct expenses. However, the company is still operating at a net loss, with a net profit margin of -10.23% and a negative EBIT and EBITDA margin, reflecting ongoing operational challenges.

Balance Sheet

The balance sheet reveals a debt-to-equity ratio of 0.62, which is manageable but indicates some leverage risk. The equity ratio stands at 26.84%, signifying that a substantial portion of the company's assets are financed through equity. ROE is negative due to net losses, pointing to challenges in generating returns for shareholders.

Cash Flow

Cash flow statement analysis shows positive operating cash flow, with an operating cash flow to net income ratio of -0.45, highlighting better cash flow management compared to earnings. The free cash flow growth rate is encouraging at -21.32% over the last year, indicating efforts towards improving cash generation.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
185.14M	180.27M	156.37M	162.05M	130.86M	91.92M
	Gross Profit
103.67M	99.52M	86.40M	87.09M	67.38M	50.76M
	EBIT
-17.54M	-14.22M	-30.05M	-34.08M	-48.94M	-58.33M
	EBITDA
-8.35M	-9.88M	-26.54M	-34.08M	-45.99M	-51.37M
	Net Income Common Stockholders
-18.95M	-20.92M	-37.49M	-42.83M	-54.38M	-59.86M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
80.92M	80.45M	65.85M	102.15M	129.36M	133.59M
	Total Assets
206.78M	200.92M	197.75M	218.09M	237.50M	221.41M
	Total Debt
99.45M	98.10M	96.00M	87.24M	87.59M	66.89M
	Net Debt
79.97M	77.83M	84.35M	51.65M	38.83M	30.30M
	Total Liabilities
150.53M	144.02M	144.30M	149.53M	151.88M	117.61M
	Stockholders Equity
55.49M	56.15M	52.65M	67.61M	84.62M	103.81M
Cash Flow		Free Cash Flow
6.71M	8.52M	-47.77M	-27.61M	-34.83M	-42.36M
	Operating Cash Flow
8.56M	11.36M	-43.17M	-25.61M	-33.92M	-40.74M
	Investing Cash Flow
-10.77M	-8.13M	8.62M	8.46M	12.69M	-49.56M
	Financing Cash Flow
474.00K	4.96M	10.67M	4.19M	34.29M	91.78M

Cerus Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.42
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CERS, the sentiment is Negative. The current price of 1.42 is above the 20-day moving average (MA) of 1.34, above the 50-day MA of 1.33, and below the 200-day MA of 1.64, indicating a neutral trend. The MACD of 0.03 indicates Negative momentum. The RSI at 50.89 is Neutral, neither overbought nor oversold. The STOCH value of 52.79 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CERS.

Cerus Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CERS	64 Neutral	$275.27M	―	-36.14%	―	13.06%	41.50%
RCEL	55 Neutral	$158.34M	―	-407.50%	―	32.24%	-66.93%
Sector *	54 Neutral	$5.38B	3.31	-45.11%	3.29%	16.82%	0.04%
ZIMV	51 Neutral	$266.65M	―	-6.35%	―	-32.70%	94.89%
SNWV	48 Neutral	$268.39M	―	0.65%	―	61.50%	34.99%
NNOX	47 Neutral	$358.98M	―	-30.11%	―	15.32%	15.73%
LUNG	46 Neutral	$136.88M	―	-60.68%	―	19.84%	5.77%

Cerus Corporate Events

Cerus Stockholders Approve Key Proposals at Annual Meeting

On June 3, 2025, Cerus Corporation held its 2025 Annual Meeting of Stockholders, where several key proposals were voted upon. Stockholders approved the amendment and restatement of the company’s 2024 Equity Incentive Plan, elected two board members, approved executive compensation, and ratified Ernst & Young LLP as the independent accounting firm for the fiscal year ending December 31, 2025.

The most recent analyst rating on (CERS) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Cerus stock, see the CERS Stock Forecast page.